AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03937596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-cycloserine
Description: Daily oral D-cycloserine 100mg during the blinded phase (10 days).
Study NCT03937596 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulator
Description: Repetitive Transcranial magnetic stimulation (rTMS) will be delivered using a MagPro X100 device with B70 coil and the intermittent theta burst (iTBS) protocol to the left dorsolateral prefrontal cortex. Participants will receive daily treatments (Monday-Friday) over four weeks.
Study NCT03937596 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcranial Magnetic Stimulator
Description: Repetitive Transcranial magnetic stimulation (rTMS) will be delivered using a MagPro X100 device with B70 coil and the intermittent theta burst (iTBS) protocol to the left dorsolateral prefrontal cortex. Participants will receive daily treatments (Monday-Friday) over four weeks.
Study NCT03937596 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Daily oral placebo during the blinded phase (10 days).
Study NCT03316248 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: visual feedback
Description: in the study group, subjects were applied for example prosthetic weight bearing exercises in front of the mirror. They watched their reflected image while doing exercises.
Study NCT03316248 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual prosthetic rehabilitation
Description: prosthetic weight bearing and balance exercises were applied to the control group for 9 sessions.
Study NCT02606617 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mosapride
Description: Mosapride(5mg, 3/d), antidiabetic drug except DPP-IV inhibitor and GLP-1 receptor activator.
Study NCT02606617 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo(5mg, 3/d), antidiabetic drug except DPP-IV inhibitor and GLP-1 receptor activator.
Study NCT01543009 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Emla + Local Warming
Description: In this arm Emla is applied 60 minutes before the procedure and then the site of venepuncture is warmed by an electric heating sand pad at the temperature of 40°C for 5 minutes before performing cannulation
Study NCT05068687 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: high-resolution PET-CT specimen imaging.
Description: Included patients are given a single weight-dependent activity of 18F-FDG at the department of Nuclear Medicine. After administration, patients are brought to the operating room where standard of care surgical removal of the malignancy is performed.~The resected specimen(s) are brought to the imaging lab and scanned using a preclinical and/or a dedicated specimen PET/CT device. Following PET/CT imaging, the specimen is brought to the department of pathology, where it is sliced. Some of these slices are then rescanned using the preclinical PET/CT device. Moreover, frozen sections are made from one of these slices with macroscopically visible malignant tissue and placed on an autoradiograph overnight. Finally, the imaging results are then correlated to the results found during histopathological analysis of the specimens.
Study NCT01283451 — intervention group
Intervention type: BEHAVIORAL
Intervention: Muscle contraction
Description: Participants will perform a 30-60 second exercise designed to cause a temporary decrease in muscle oxygenation of a specific muscle group.
Study NCT01314339 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desloratadine
Description: Desloratadine Tablets, 5 mg
Study NCT01314339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desloratadine
Description: Desloratadine Tablets, 5 mg
Study NCT03278223 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Test solution
Description: A Multi-purpose soft contact lens care solution containing polyaminopropyl biguanide, polyquaternium-2.
Study NCT03278223 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control solution
Description: A Multi-purpose soft contact lens care solution containing polyaminopropyl biguanide, polyquaternium-1.
Study NCT00944138 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation methods
Description: Relaxation methods will include mindful meditation techniques for the intervention and listening to music for the control arm
Study NCT01814371 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2% mupirocin ointment
Description: Participants over 1 month of age, apply ointment to the anterior nares twice daily for 5 days.
Study NCT01814371 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bleach Bath (dilute)
Description: Participants over 1 month of age, pour 1/4 cup of bleach into a bath tub filled 1/4 full of water. Soak in bath for 15 minutes daily for 5 days.
Study NCT01814371 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hygiene Protocol
Description: Follow key hygiene tips:~* Throw out all lotions or creams that you dip your hands into and replace with pumps or pour bottles.~* Use liquid(pour or pump) soaps instead of bar soaps.~* Wash hands frequently or use hand sanitizer(with more than %60 alcohol) such as Germ-X or Purell.~* Do not share personal care items such as razors, brushes, or deodorant.~* Wash all sheets and towels in hot water. Wash sheets every week.~* Use towels and wash cloths only once before washing and do not share.
Study NCT05308173 — intervention group
Intervention type: PROCEDURE
Intervention: Surgical Aortic Valve Replacement
Description: Cardiac surgery under cardio-pulmonary bypass, via sternotomy or minimally invasive approach with the replacement of native valve with a biological or mechanic prosthesis.
Study NCT05308173 — intervention group
Intervention type: PROCEDURE
Intervention: Transcutenous Aortic Valve Implantation
Description: Transfemoral implantation of aortic bioprosthesis with one of the devices available in Poland.
Study NCT01854827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG)
Description: All participants will receive the same dose of IVIG at the same intervals in an open-label fashion as long as the subject does not have any increased risk for toxicity for any IVIG infusion. IVIG will be initiated on day 3 (up to day 5) after HPE surgery (HPE is day 0) at a dose of 1 gm/kg body weight by slow intravenous infusion over at least 4 hours. The same dose (1 gm/kg) and duration of infusion will be repeated on day 30 and day 60 after HPE.
Study NCT04829370 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PLT
Description: The study will be conducted by using a fractional carbon dioxide laser for acne scar treatment. After the treatment, each patient enrolled will be applied 2 mL PLT solution on the right face. Treatment mentioned above will be repeated every 3 to 4 weeks, overall 4 times treatment and one month follow up after fourth treatment. Every record will be documented in questionnaires by the principal investigator and the patient itself. Moreover, VISIA is applied for objective observation, such as spots, wrinkles, texture, pores, UV spots, brown spots, red area, and porphyrins could be objectively analyzed.
Study NCT02359552 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rasagiline
Study NCT02359552 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03985826 — intervention group
Intervention type: OTHER
Intervention: Diagnosis of and treatment for Acute lymphoblastic leukaemia in childhood
Description: The cohort of ALL survivors has all been diagnosed and treated for ALL in childhood
Study NCT02053402 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Vitamin D daily for six months
Study NCT04627259 — intervention group
Intervention type: OTHER
Intervention: Thumb Disability Examination
Description: Turkish Version of Thumb Disability Examination. The Turkish Version of Thumb Disability Examination consists of 20 questions related with thumb pain and functionality.
Study NCT05416970 — intervention group
Intervention type: BEHAVIORAL
Intervention: SUPERIMPOSED SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS-2 (SARS-CoV-2) LIFESTYLE CHANGES
Description: To assess the impact of the SARS-CoV-2 spread related lifestyle changes on body composition analysis and metabolic syndrome components worsening as well as hepatocellular carcinoma occurrence.
Study NCT02573883 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fractionated Carbon Dioxide Laser
Description: Vulvar lichen sclerosis will be treated except for the clitoris glans and clitoral hood which will be spared with at least 5mm margin. The procedure will be performed in the outpatient clinic at the National Center for Advanced Pelvic Surgery at MedStar Washington Hospital Center Lafayette Office, 1133 21st St NW, Washington, DC 20036, and include 3 sessions, 4 weeks apart.
Study NCT02573883 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fractionated Carbon Dioxide Laser
Description: Vulvar lichen sclerosis will be treated except for the clitoris glans and clitoral hood which will be spared with at least 5mm margin. The procedure will be performed in the outpatient clinic at the National Center for Advanced Pelvic Surgery at MedStar Washington Hospital Center Lafayette Office, 1133 21st St NW, Washington, DC 20036, and include 3 sessions, 4 weeks apart.
Study NCT02573883 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clobetasol Propionate 0.05% ointment
Description: Topical Steroid therapy (Clobetasol propionate .05% ointment nightly for one month then three times weekly for 2 additional months) for a total of three months of treatment.
Study NCT02573883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clobetasol Propionate 0.05% ointment
Description: Topical Steroid therapy (Clobetasol propionate .05% ointment nightly for one month then three times weekly for 2 additional months) for a total of three months of treatment.
Study NCT03653689 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: FODMAP
Description: The intervention will run for seven weeks. During the whole intervention, the participants will hold a baseline diet with no gluten and low intake of FODMAPs. The first week, the participants will consume a one-time cocktail provocation consisting of gluten (17.3 gram) and FODMAPs (50 gram) Thereafter, study participants will receive three 1-week diets with additions of either FODMAPs, gluten or an inert control with 1-week washout in-between. The daily amount for gluten will be 17.3 gram and the daily amount for FODMAPs will be 50 gram. The order of the three weeks with extra diets (gluten/FODMAPs/control) will be randomized.
Study NCT03653689 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: FODMAP
Description: The intervention will run for seven weeks. During the whole intervention, the participants will hold a baseline diet with no gluten and low intake of FODMAPs. The first week, the participants will consume a one-time cocktail provocation consisting of gluten (17.3 gram) and FODMAPs (50 gram) Thereafter, study participants will receive three 1-week diets with additions of either FODMAPs, gluten or an inert control with 1-week washout in-between. The daily amount for gluten will be 17.3 gram and the daily amount for FODMAPs will be 50 gram. The order of the three weeks with extra diets (gluten/FODMAPs/control) will be randomized.
Study NCT03653689 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Gluten
Description: The intervention will run for seven weeks. During the whole intervention, the participants will hold a baseline diet with no gluten and low intake of FODMAPs. The first week, the participants will consume a one-time cocktail provocation consisting of gluten (17.3 gram) and FODMAPs (50 gram) Thereafter, study participants will receive three 1-week diets with additions of either FODMAPs, gluten or an inert control with 1-week washout in-between. The daily amount for gluten will be 17.3 gram and the daily amount for FODMAPs will be 50 gram. The order of the three weeks with extra diets (gluten/FODMAPs/control) will be randomized.
Study NCT03653689 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Gluten
Description: The intervention will run for seven weeks. During the whole intervention, the participants will hold a baseline diet with no gluten and low intake of FODMAPs. The first week, the participants will consume a one-time cocktail provocation consisting of gluten (17.3 gram) and FODMAPs (50 gram) Thereafter, study participants will receive three 1-week diets with additions of either FODMAPs, gluten or an inert control with 1-week washout in-between. The daily amount for gluten will be 17.3 gram and the daily amount for FODMAPs will be 50 gram. The order of the three weeks with extra diets (gluten/FODMAPs/control) will be randomized.
Study NCT03653689 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: The intervention will run for seven weeks. During the whole intervention, the participants will hold a baseline diet with no gluten and low intake of FODMAPs. The first week, the participants will consume a one-time cocktail provocation consisting of gluten (17.3 gram) and FODMAPs (50 gram) Thereafter, study participants will receive three 1-week diets with additions of either FODMAPs, gluten or an inert control with 1-week washout in-between. The daily amount for gluten will be 17.3 gram and the daily amount for FODMAPs will be 50 gram. The order of the three weeks with extra diets (gluten/FODMAPs/control) will be randomized.
Study NCT03653689 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The intervention will run for seven weeks. During the whole intervention, the participants will hold a baseline diet with no gluten and low intake of FODMAPs. The first week, the participants will consume a one-time cocktail provocation consisting of gluten (17.3 gram) and FODMAPs (50 gram) Thereafter, study participants will receive three 1-week diets with additions of either FODMAPs, gluten or an inert control with 1-week washout in-between. The daily amount for gluten will be 17.3 gram and the daily amount for FODMAPs will be 50 gram. The order of the three weeks with extra diets (gluten/FODMAPs/control) will be randomized.
Study NCT01463397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR292833
Description: Pharmaceutical form: capsule~Route of administration: oral
Study NCT01463397 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Pharmaceutical form:capsule~Route of administration: oral
Study NCT00400257 — intervention group
Intervention type: BEHAVIORAL
Intervention: Early detection of heart failure
Description: Early detection of heart failure
Study NCT04934124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITI-333
Description: ITI-333 oral solution
Study NCT04934124 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo
Study NCT04829370 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: The study will be conducted by using a fractional carbon dioxide laser for acne scar treatment. After the treatment, each patient enrolled left face be applied 2 mL normal saline.~Treatment mentioned above will be repeated every 3 to 4 weeks, overall 4 times treatment and one month follow up after fourth treatment. Every record will be documented in questionnaires by the principal investigator and the patient itself. Moreover, VISIA is applied for objective observation, such as spots, wrinkles, texture, pores, UV spots, brown spots, red area, and porphyrins could be objectively analyzed.
Study NCT01102985 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: aerobic resistance exercise
Description: three times per week aerobic resistance exercise for 12 months
Study NCT01102985 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: home based health promotion
Description: education and support to adapt national guidelines for 30 minutes physical activity most days of the week
Study NCT03861078 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Own Brand Cigarette
Description: Effects of own brand cigarette use.
Study NCT03861078 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ECIG 15 mg nicotine, sweetened
Description: Effects of using a 30 Watt ECIG filled with 15 mg nicotine, sweetened liquid
Study NCT03861078 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ECIG 15 mg nicotine, unsweet
Description: Effects of using a 30 Watt ECIG filled with 15 mg nicotine, unsweet liquid
Study NCT03861078 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ECIG 0 mg nicotine, sweetened
Description: Effects of using a 30 Watt ECIG filled with 0 mg nicotine, sweetened liquid
Study NCT03861078 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ECIG 0 mg nicotine, unsweet
Description: Effects of using a 30 Watt ECIG filled with 0 mg nicotine, unsweet liquid
Study NCT05165563 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Treatment of implant single crown
Description: Digital or Conventional Workflows for treatment of implant single crown and materials used.
Study NCT03878290 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resilience, Stress, and Ethnicity (RiSE)
Description: Group based stress reduction program focused on helping minorities develop coping and empowerment skills
Study NCT03418701 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Smart for Weight Loss
Description: We will test the effectiveness of a culturally sensitive, evidence-based, multi-component, behavioral program for treating obesity called Health-Smart. This program will be implemented for 6 months in 20 UF Health Jacksonville primary care clinics by Community Health Workers (CHWs) with Black women patients who have obesity, and followed by either of two physician-implemented behavioral counseling weight loss maintenance programs that are applied quarterly over 12 months to prevent weight gain. Specifically, we will compare the effects on weight-loss and weight-loss maintenance of (1) Health-Smart plus the Patient-Centered, Culturally Sensitive Weight Loss Maintenance Program (PCS-WLM), and (2) Health-Smart plus the Standard Behavioral Weight Loss Maintenance Program (SB-WLM).
Study NCT03779334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risdiplam
Description: Risdiplam will be administered orally.
Study NCT01248143 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Green tea
Description: 9 gram per day
Study NCT01248143 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: FPP
Description: 2 sachets twice daily
Study NCT04382807 — intervention group
Intervention type: BEHAVIORAL
Intervention: Counseling
Description: Online delivered group counseling session, providing insights into the tinnitus symptoms
Study NCT03120949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olokizumab 64 mg SC q4w
Description: 160 mg/mL sterile solution for SC injection in a 2 mL clear Type I glass vial with target volume of 0.4 mL or in the pre-filled syringe (PFS).PFS is composed of a 1 mL clear Type I glass barrel vial with target volume of 0.4 mL.
Study NCT03120949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olokizumab 64 mg SC q2w
Description: 160 mg/mL sterile solution for SC injection in a 2 mL clear Type I glass vial with target volume of 0.4 mL or in the pre-filled syringe (PFS). PFS is composed of a 1 mL clear Type I glass barrel vial with target volume of 0.4 mL.
Study NCT03120949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Concomitant treatment
Description: Methotrexate 15 to 25 mg/week (or ≥ 10 mg/week if there was documented intolerance to higher doses). (Subject maintained their stable dose and route (oral, SC, or IM) during the core study and for ≥ 12 additional weeks of OLE.)~Folic acid ≥ 5 mg per week or equivalent
Study NCT02103426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP0113
Description: intramuscular injection
Study NCT02103426 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intramuscular injection
Study NCT01247922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: continuous oral Erlotinib 85 mg/m\^2 per day
Study NCT04475497 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood management
Description: The intervention will include pre-surgical optimization blood management referral based on pre-operative Hgb levels \<11.0 g/dL. Treatment will include PO iron, IV iron, B12 or folate per blood management algorithm.
Study NCT04475497 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care per surgeon preference can include iron by mouth or no iron therapy.
Study NCT04476849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fezolinetant
Description: Oral
Study NCT02215200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Thymocyte Globulin (ATG)
Description: Thymoglobulin
Study NCT00240097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intervention A: Irinotecan; Oxaliplatin; Neulasta
Description: Irinotecan (I.V.) 150-200 mg/m2; Day 1 (every 5 weeks) Oxaliplatin (I.V.) 85 mg/m2; Day 1 (every 5 weeks) Neulasta (subcutaneous) 6 mg; Day 1 (every 5 weeks)
Study NCT00240097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intervention B: Etoposide; Carboplatin; Neulasta
Description: Etoposide (I.V.) 100 mg/m2; Day 1, 2, 3 (every 5 weeks) Carboplatin (I.V.) AUC 6; Day 1 (every 5 weeks) Neulasta (subcutaneous) 6 mg; Day 4 (every 5 weeks)
Study NCT03093233 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: only descriptive data analysis
Study NCT01601925 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: supine extended position of the neck
Description: we measure the distances from cricoid cartilage to C6 or C7 transverse process in supine neutral and extended position of the neck